From venom to medicine
Research into the venom of a South American pit viper in the 1960s helped open a new route towards treating high blood pressure, demonstrating how a substance capable of causing harm can also provide clues for developing medicines. The work centred on Bothrops jararaca, commonly known as the Brazilian lancehead or jararaca, a snake native to parts of South America, including Brazil.
The scientific importance of the research lay not in using the venom as a treatment, but in examining the biological effects of its components. Investigators found compounds that affected mechanisms involved in regulating blood pressure. Their findings eventually contributed to the development of captopril, an oral drug for hypertension that was approved in the United States in 1981.
A pharmacological lead from snake venom
The research is associated with Brazilian pharmacologist Sergio Ferreira, who began this work in 1965. In a paper based on his PhD thesis and published in the British Journal of Pharmacology, Ferreira described the action of an extract from the snake's venom.
The extract was found to enhance the effects of bradykinin, a naturally occurring peptide involved in widening blood vessels and thereby lowering blood pressure. This observation provided researchers with a useful biological lead. Rather than treating the venom as a single substance, scientists began examining the individual molecules responsible for its effects.
Further investigation identified small molecules known as bradykinin-potentiating peptides. These compounds became significant as researchers worked to understand how they interacted with the body's systems for controlling blood pressure. One enzyme that received particular attention was angiotensin-converting enzyme, or ACE.
Why the discovery mattered
The progression from venom research to a prescription medicine illustrates the value of studying natural products at the molecular level. A snake's venom is a complex biological mixture, and its effects can be dangerous. However, examining those effects can reveal specific interactions that may be adapted for therapeutic use under controlled conditions.
In this case, the Brazilian lancehead provided the starting point for research into compounds linked with blood-vessel widening and blood-pressure regulation. The subsequent development of captopril marked a shift in cardiovascular medicine by providing an oral option for managing hypertension. The drug's approval in the US in 1981 placed the findings from the earlier venom studies within the wider history of modern drug development.
| Scientific development | Information available from the research |
|---|---|
| Animal studied | Bothrops jararaca, the Brazilian lancehead |
| Research period | Beginning in 1965 |
| Key biological lead | Compounds that enhanced bradykinin activity |
| Medicine linked to the work | Captopril, approved in the US in 1981 |
A wider lesson for medical research
The episode also underlines how discoveries in medicine can emerge from studies that initially appear far removed from clinical care. The investigation began with the biological properties of a harmful substance. By isolating and studying its active components, researchers were able to identify mechanisms relevant to blood-pressure control and create a pathway towards a drug.
It remains an example of translational science: observations made through basic research can, over time, influence treatments used in cardiovascular medicine. The story of the jararaca venom does not suggest that natural substances are automatically safe or suitable as medicines. Instead, it shows the importance of precise laboratory investigation, identification of individual compounds and a clear understanding of how they affect the human body's regulatory systems.
- The Brazilian lancehead's venom was studied for its effects on blood-pressure-related processes.
- Ferreira's 1965 work identified an extract that strengthened bradykinin activity.
- The findings contributed to captopril, an oral hypertension drug approved in the United States in 1981.
